Champigny Sur Marne

Researchers are evaluating two early screening methods to identify infants at risk of Autism Spectrum Disorder and Neurodevelopmental Disorders. This study focuses on infants under 12 months old receiving care at Maternal and Child Protection Services in France. The goal is to provide early detection and referral to specialized care to improve outcomes for these children. During the usual medical visits at 4 and 9 months, two screening strategies will be tested: one using routine assessments of motor skills, vocalizations, babbling, and social interactions by health professionals, and another using the PREAUT grid specifically designed for autism screening. Infants with abnormal results will be referred promptly to specialized centers for further advice and treatment, ideally within one month of the initial consultation. Participants will be followed up at 12, 24, and 36 months with developmental assessments including the Modified Checklist for Autism in Toddlers and the French Child Development Inventory. Additional diagnostic tools will be used if initial screens are abnormal. Data on treatments received will be collected, and health insurance claims will be analyzed up to 48 months to evaluate care pathways. The primary outcome is the proportion of children diagnosed by 24 months who received care before age one.

Researchers are comparing two anesthesia methods for patients undergoing hand surgery: neuroleptanalgesia and hypnoanalgesia, both combined with locoregional anesthesia by truncal block. The study is designed to assess changes in preoperative anxiety and evaluates other outcomes such as pain during surgery, surgery duration, hospital stay, use of sedatives, patient satisfaction, and adverse events. This is a single-center, prospective, randomized, open-label study involving two parallel groups. One group receives the usual neuroleptanalgesic treatment with Hypnovel plus locoregional anesthesia, while the other group receives hypnoanalgesia alongside locoregional anesthesia. Both treatment protocols are administered during outpatient hand surgeries like upper limb trunk blocks for procedures such as flexor teno synovectomy or endoscopic carpal tunnel surgery. Sedation is required in addition to locoregional anesthesia for all participants. Participants will have their anxiety measured before and after surgery using a visual analog scale (VAS) from 0 to 10. Researchers will also monitor intraoperative pain, post-operative pain, duration of surgery and hospitalization, additional sedative use, patient satisfaction, and any adverse events during and immediately after surgery. The main outcome focuses on VAS anxiety scores on the second day. The study includes adults aged 18 to 80 years and involves signing informed consent before participation.

Researchers are evaluating the use of olaparib in adult male patients with metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting across multiple centers in France. This observational longitudinal study aims to understand how olaparib is used in treatment sequences, its effectiveness, safety, and patterns of BRCA genetic testing to help improve future clinical care for this condition. The study includes patients who have started olaparib treatment within the last two months before joining the study or who participated in an early access program funded for olaparib use. Treatment decisions are made by the patients' physicians, and researchers observe and collect data without intervening. The study follows patients for up to 24 months from the start of olaparib treatment to track how long they continue the treatment and other outcomes. Participants will be monitored through their routine medical care, and data will be collected on treatment duration, safety, and BRCA testing patterns. The main outcome measured is the time until patients stop olaparib treatment, observed over a period of up to two years. The study relies on patient records and does not involve additional experimental procedures, focusing on real-life treatment experiences and outcomes.

This research aims to observe patients in France who have HER2-negative early breast cancer and are treated with olaparib. The study focuses on understanding how many patients complete the full planned course of olaparib treatment, which is given as adjuvant therapy following initial cancer treatment. It is a national, multicenter, prospective cohort study conducted without altering the usual care provided by doctors. Patients enrolled will be those starting adjuvant olaparib treatment based on their doctor's decision. There are no experimental interventions or treatment changes imposed by the study. The study captures real-world use of olaparib across multiple centers in France. Participants will be followed for at least 18 months after joining the study to see if they complete the full duration of olaparib treatment. Researchers will collect data on treatment adherence and other relevant clinical information during this period. The main outcome measured is the proportion of patients who receive olaparib for the entire planned treatment period.